Abbott Laboratories (ABT) Tops Q4 EPS by 4c; Raises FY12 Guidance
Tweet
Share
E-mailGet Alerts ABT Hot Sheet
Price: $108.33 -0.42%
EPS Growth %: +9.2%
Financial Fact:
Interest expense: 117M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +9.2%
Financial Fact:
Interest expense: 117M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Abbott Laboratories (NYSE: ABT) reported Q4 EPS of $1.03, $0.04 better than the analyst estimate of $0.99. Revenue for the quarter came in at $9.46 billion versus the consensus estimate of $9.35 billion.
Abbott Laboratories sees FY2012 EPS of $5.00-$5.10, versus prior guidance of $4.95-$5.05 and the consensus of $5.01.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Abbott Laboratories sees FY2012 EPS of $5.00-$5.10, versus prior guidance of $4.95-$5.05 and the consensus of $5.01.
For earnings history and earnings-related data on Abbott Laboratories (ABT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Bernstein SocGen Group Reiterates Outperform Rating on Zydus Lifesciences (ZYDUSLIF:IN)
- BlackRock’s Rosenberg says inflation data key after jobs beat
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
